Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2117 of 5804
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control AVAILABLEThe purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at leas…
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New imaging tool helps doctors see brain tumors more clearly
Diagnosis AVAILABLEThe participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's…
Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
ALS patients get expanded access to experimental Sugar-Based drug
Disease control NO_LONGER_AVAILABLEThis expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
Sponsor: Seelos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:42 UTC
-
Last-Resort access to dupilumab for patients with severe inflammation
Disease control APPROVED_FOR_MARKETINGProvide Compassionate Use of Dupilumab
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug hope for stubborn hives patients
Disease control AVAILABLEThe purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide access to remibrutinib for adult patients with chronic spontaneous urticaria (CSU)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Last-Resort drug access: asciminib opens for CML patients
Disease control AVAILABLEThe purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for MS patients: drug access program opens for those with no alternatives
Disease control NO_LONGER_AVAILABLEThe purpose of this MAP Cohort Treatment Plan is to allow access to siponimod for eligible patients diagnosed with Secondary Progressive Multiple Sclerosis with active disease. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for CIDP patients: early access to efgartigimod drug
Disease control AVAILABLEThe aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options. The program will continue until the patient discont…
Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Early access program offers investigational meningioma treatment
Disease control AVAILABLEThis Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´…
Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Unapproved device trial aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Second chance: experimental access to CAR T-Cell therapy for patients whose treatment batches Don't meet commercial standards
Disease control AVAILABLEThe goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Last-Resort drug access opens for aggressive breast cancer patients
Disease control AVAILABLEThis Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.
Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for catheter patients: expanded access to Infection-Fighting drug DefenCath
Prevention NO_LONGER_AVAILABLEThe EAP for DefenCath is designed to provide access to a broader population of adult and pediatric patients using catheters for various serious medical conditions. A key aspect of this EAP is its focus on individuals who, due to their unique clinical circumstances, are either ine…
Sponsor: CorMedix • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Aggressive chemo plus stem cell transplant tested for breast cancer
Disease control CompletedTo determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New daily pill for breast cancer now available through early access program
Disease control AVAILABLEThe primary objective of this expanded access program (EAP) is to provide early access to giredestrant for participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC) or locally advanced/metastatic breast…
Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Experimental device aims to tame disease without drugs
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lifeline for kids with severe epilepsy: drug access extended
Disease control AVAILABLEThis is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental device aims to tame disease without drugs
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC